ClinicalTrials.gg

Program

ARO-ALK7

Its studies are mostly in Obesity, led by Arrowhead Pharmaceuticals.

Furthest: phase 2, since Apr 15, 20251 company-led study, 1 open or runningNext primary completion: Feb 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Arrowhead Pharmaceuticals11 open or runningphase 2since Apr 15, 2025Apr 15, 2025Feb 2027phase 2 · NCT06937203

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 15, 2025First study: phase 2 study in ObesityFirst studyNCT06937203 · 150 planned · Australia, New Zealand

Ahead

  1. Feb 2027Primary completion: phase 2 study in ObesityNCT06937203

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06937203Obesity · Australia, New Zealand2RecruitingFeb 2027150

How it is read

Names in the registry

  • “ARO-ALK7”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.